Dataset Information

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND2)

ABSTRACT: Interventions: Group 1: one blood draw in cancer patients (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, uterine cancer, kidney/renal pelvis cancer, pancreatic cancer, liver cancer, stomach cancer, ovarian cancer, esophageal cancer, head and neck squamous cell cancer, thyroid cancer, small intestine cancer, cervical cancer, anal cancer, vulva cancer, testicular cancer) after study consent Group 2: one blood draw in healthy subjects Primary outcome(s): The primary objective of this study is to obtain clinically characterized, whole blood specimens from cancer and healthy subjects to develop and refine assays for cancer in the blood. Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other

DISEASE(S): Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Bladder Cancer, Uterine Cancer, Kidney/renal Pelvis Cancer, Pancreatic Cancer, Liver Cancer, Stomach Cancer, Ovarian Cancer, Esophageal Cancer, Head And Neck Squamous Cell Cancer, Thyroid Cancer, Small Intestine Cancer, Cervical Cancer, Anal Cancer, Vulva Cancer, Testicular Cancer

PROVIDER: 93757 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:PURPOSE: Amino acids (AAs) play important physiological roles in living cells. Some amino acid changes in blood are specific for autoimmune disorders, and some are specific for thyroid cancer. The aims of this study were to profile AA metabolites in the serum of patients with papillary thyroid carcinoma (PTC0) without Hashimoto’s thyroiditis (HT) and patients with PTC with HT (PTC1) and predict whether AA metabolites are associated with thyroid disease, thyroid hormone and thyroid autoantibodies. METHODS: A total of 93 serum samples were collected, including 28 healthy controls (HCs), 28 PTC0 patients and 37 PTC1 patients. Serum samples were analysed by high-performance liquid chromatography-triple stage quadrupole-mass spectrometry (HPLC-TSQ-MS), and 21 amino acids (AAs) were detected.RESULTS: The serum concentration of glutamic acid was significantly elevated in PTC1 patients compared with PTC0 patients. Lysine was the second amino acid that differentiated these two groups of PTC patients. In addition, the serum concentrations of glycine, alanine and tyrosine were significantly reduced in both PTC patient groups compared to the HC group. These AAs were also correlated with thyroid hormones and antibodies. Five amino acid markers, namely, glycine, tyrosine, glutamic acid, glutamine and arginine, separated/distinguished PTC0 patients from healthy subjects, and eight AA markers, the same AAs as above without arginine but with alanine, leucine, valine and histidine, separated/distinguished PTC1 patients from healthy subjects based on ROC analysis.CONCLUSION: Compared with the HCs, changes in AAs in PTC0 and PTC1 patients showed similar patterns, suggesting the possibility of a common pathophysiological basis, which confirms preliminary research that PTC is significantly associated with pathologically confirmed HT. We found two AAs, lysine and alanine, that can perform diagnostic functions in distinguishing PTC1 from PTC0.

Dataset Information

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND2)

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure